MannKind Corporation - Jefferies Global Healthcare Conference in London - MANNKIND CORP
Financial Performance:
- Reported a 42% CAGR over the last five years driven by royalties, commercial collaboration revenue, and in-line growth from Furoscix and Afrezza.
- Expects to achieve profitability in Q4 2026 with record revenues for the quarter.
- Q3 revenue growth was reaccelerated following a period where the DPI business acted as a headwind; Furoscix ReadyFlow shipments show 75% conversion rate and are driving strong demand.
- Anticipates generating approximately $1 billion in cumulative revenue from manufacturing royalties and collaboration fees between 2026 and 2030.
- Q4 2026 revenue guidance is estimated at $38 million, subject to +/- variance.
Guidance and Future Outlook:
- Identifies three major engines for growth: commercial revenue expansion (Furoscix ReadyFlow, Fresa Pediatrics), the UT collaboration (Tyvaso DPI, Verlaine-Opeg), and the long-term entry into IPF via Natentenib DPI.
- Targets the IPF market with three assets: Relenopeg, Tyvaso DPI, and Natentenib.
- Plans to file a 40mg Furoscix formulation next year, with readout expected in the first half of 2028.
- Aiming to launch a high-concentration Afrezza formulation for Type 2 diabetes in 2028 to address the need for 16-20 units per meal in a single inhalation.
- Expecting the RELenopeg oral tablet to potentially receive approval in 2027.
- Natentenib Phase 2 data readout is currently projected for the first half of 2028, with potential to accelerate to early 2028 by expanding to US sites.
Business Segments and Product Lines:
- Furoscix: 75% of shipments converted within the first few weeks; 90% of community prescriptions are for the ReadyFlow device. The "worsening at home" segment drives 90% of current sales, with significant opportunity to expand into emergency department, hospital IV, and post-discharge readmission segments.
- Afrezza: Pediatric launch achieved 80% growth in new-to-brand prescriptions; pediatric market share is twice that of the adult segment in the first 90 days. Plans to double down on adult sales in 2027 with expanded nephrology and cardiology coverage.
- Afrezza Innovations: Launching a two-unit low-dose cartridge and "Inhale IQ" (digital adapter integrating inhaler data with CGM) in 2027. The "Inhale First" pediatric trial now includes 35 patients, targeting 100 by mid-2027.
- Collaboration (United Therapeutics): Mankind is the sole manufacturer for Tyvaso DPI; manufacturing capacity expanded to support up to 250,000 patients. UT is advancing Tyvaso into IPF/PPF trials and launching Verlaine-Opeg (once-daily prostacyclin) with Milestone payments expected.
- Natentenib DPI: Moving into Phase 2 (INFLOW2) with ~150 patients across 100 sites in the US; trial size reduced from 220 to 153 to focus on a twice-daily dosing regimen.
Market and Competitive Landscape:
- Furoscix has rapidly displaced All-In-One Infusers (OBI), capturing 56% market share within four weeks of launch and 73% within eight weeks, currently averaging over 50% shipment doses.
- The Furoscix platform addresses fluid overload in CKD and hospital settings, with the goal of preventing hospitalization, expediting discharges, and reducing readmissions across a market of nearly 4 million patients across four segments.
- The IPF market is characterized by high failure rates; management highlights a significant unmet need for tolerable, effective treatments.
- Natentenib tolerability data shows 60% of IPF patients reported no increase in cough, addressing a primary barrier to inhaled dry powder therapies in this population.
Risks and Challenges:
- Clinical Development: Natentenib faces the challenge of proving efficacy in Phase 2 after a slow enrollment pace necessitated by protocol changes (shift from QID to BID dosing).
- Commercial Execution: Adult Afrezza sales experienced softness in 2026 due to a strategic pivot to support Furoscix and pediatric integration; requires renewed sales force focus to reverse trends.
- Complexity of Launch: Penetrating the Emergency Department segment for Furoscix remains difficult due to systemic complexities.
- Market Dynamics: The IPF space is historically littered with therapeutic failures, presenting execution risk for Natentenib and Relenopeg.
Management Commentary and Tone:
- Tone is highly confident and optimistic, emphasizing a "very quick journey" of growth and the potential for a "bright future."
- Management expressed pride in the manufacturing capacity expansion and the durability of the UT collaboration revenue stream despite initial market skepticism.
- Highlighted successful FDA interactions regarding Natentenib's Phase 2 design, noting clear feedback that the trial is well-structured.
- Acknowledged the strategic error of shifting focus away from the adult Afrezza portfolio but stated a clear "double down" strategy for 2027.
Analyst Questions and Answers:
- Question on Natentenib Tolerability: Management confirmed no patient discontinuations due to cough in the 7-day Phase 1b trial, citing that patients with IPF often cough frequently and do not view mild cough as a major deterrent.
- Question on Efficacy: While not definitive, management expects Phase 2 data to support efficacy, with a focus on the 4mg BID dose being the preferred target.
- Question on Manufacturing: Confirmed Mankind is the sole source manufacturer for Tyvaso DPI following a strategic shift from UT's North Carolina facility, ensuring long-term economic visibility.
- Question on Pediatric Afrezza: Clarified that the pediatric approval also validated the safety of the adult product and allowed for the correction of historical underdosing (fixed by ~50%).
Other Key Points:
- The company has secured a $45 million milestone payment from Frazier for securing ReadyFlow approval in August.
- The "Inhale First" trial aims to change the standard of care by administering inhaled insulin to newly diagnosed children within 10 days of hospitalization to break the "pump mindset."
- Digital integration via "Inhale IQ" addresses adherence concerns by allowing parents and doctors to verify dosing events, a capability missing with traditional insulin pumps.
- The company expects to transition from a period of mixed growth (headwinds in DPI, softness in adult Afrezza) to a reacceleration phase driven by Furoscix expansion and Afrezza pediatric momentum in Q4 2026.
- Company
- MANNKIND CORP
- Keywords
- MANNKIND CORP